Geode Capital Management LLC Sells 8,632 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Geode Capital Management LLC reduced its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 1.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 822,352 shares of the specialty pharmaceutical company’s stock after selling 8,632 shares during the period. Geode Capital Management LLC owned 1.66% of KalVista Pharmaceuticals worth $6,967,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in KALV. Barclays PLC increased its holdings in KalVista Pharmaceuticals by 418.5% in the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock worth $778,000 after purchasing an additional 54,257 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of KalVista Pharmaceuticals by 8.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock valued at $262,000 after acquiring an additional 1,670 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in shares of KalVista Pharmaceuticals during the 4th quarter valued at $634,000. SG Americas Securities LLC boosted its stake in KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 1,319 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after purchasing an additional 2,043 shares during the period.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. JMP Securities assumed coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price target on the stock. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Finally, TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price target for the company. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $24.83.

KalVista Pharmaceuticals Trading Up 3.5 %

Shares of KalVista Pharmaceuticals stock opened at $12.88 on Friday. The company has a market capitalization of $640.34 million, a P/E ratio of -3.54 and a beta of 0.39. The stock has a fifty day simple moving average of $11.55 and a 200 day simple moving average of $10.35. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $15.50.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par purchased 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 9th. The stock was bought at an average cost of $9.42 per share, with a total value of $235,500.00. Following the completion of the transaction, the insider now owns 5,303,985 shares of the company’s stock, valued at $49,963,538.70. The trade was a 0.47 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 5,104 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $50,121.28. Following the completion of the transaction, the chief executive officer now directly owns 278,855 shares in the company, valued at approximately $2,738,356.10. This represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders bought 261,055 shares of company stock worth $2,397,646 and sold 17,292 shares worth $184,625. Company insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).